To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
New drug prevents spread of human prostate cancer cells
Drug halts disease by turning off the 'go' switch in cancer cells
05-04-2012: A new drug developed by Northwestern Medicine scientists prevented human prostate cancer cells from spreading to other tissues without any toxic effects to normal cells or tissues. The drug turns off the "go" switch in the cancer cells and immobilizes them.
"This is an extremely promising new therapeutic that locks down aggressive prostate cancer cells so they don't move," said Raymond Bergan, M.D., director of experimental therapeutics for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "The spread of prostate cancer is what kills men. Cancer cells have a switch that tells them to keep moving all the time. This drug turns it off."
The drug works by binding to and disabling proteins in the cancer cell that instruct it to move, said Bergan, a professor of medicine at Northwestern's Feinberg School of Medicine and a physician at Northwestern Memorial Hospital.
The research was presented at the American Association for Cancer Research Annual Meeting 2012 in Chicago by Li Xu, a research assistant professor of medicine at the Feinberg School. She helped develop the drug, along with Karl Scheidt, an associate professor of chemistry at the Weinberg College of Arts and Sciences.
In the study, Northwestern researchers transplanted aggressive human prostate cancer cells into mice prostate tissue and fed the mice with the new drug for five weeks. The drug inhibited movement of the cells and prevented them from metastasizing to the lung, one of the tissues to which prostate cancer spreads in men.
Xu said she conducted extensive toxicity studies, including on normal human cells, and found that the drug, called KBU2046, is nontoxic and does not cause any harmful effects.
"We envision that this drug, if shown to be effective in clinical trials, could be used to treat men diagnosed with prostate cancer, so they wouldn't need more aggressive procedures," Bergan said. "Or, the drug could augment the effectiveness of surgery and radiation."
Contact / Request information
Request further information free of charge:
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Vivacta Initiates Development of Point of Care Test for Vitamin D
- 4Using human brain cells to make mice smarter
- 5Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 6Fighting listeria and other food-borne illnesses with nanobiotechnology
- 7A light switch inside the brain
- 8Researchers divide enzyme to conquer genetic puzzle
- 9New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 10Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd
- Unique method creates correct mirror image of molecule
- KI becomes first university in Sweden to offer open online courses for a glo ...
- Successful results in developing oral vaccin against diarrhea
- Stratified Medicine Scotland Innovation Centre appoints chairman
- Innovative medication to shatter blood clots with light